Although, on average, 10% of women diagnosed with breast cancer are estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative (i.e., triple-negative breast cancer; TNBC), this proportion increases to 19% of cases in Non-Hispanic Black women [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.